Clinigen agrees to buy U.S. rights to Novartis' cancer drug Proleukin

British pharmaceutical firm Clinigen Group Plc said on Wednesday it had agreed to acquire the U.S. rights to Swiss drugmaker Novartis AG's skin and lung cancer drug Proleukin for a total of $210 million, including some future payments.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news